Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
about
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature.An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.Identifying and managing the adverse effects of immune checkpoint blockade.Management of adverse events related to checkpoint inhibition therapy.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumabClinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimenPD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancerA case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumabImmune-Related Thyroiditis with Immune Checkpoint InhibitorsInfliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisA severe case of neuro-Sjögren's syndrome induced by pembrolizumabTrial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statementImportance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitisClinical Safety of Combined Targeted and L. Therapy in Oncological PatientsImmune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinomaNivolumab-induced cold agglutinin syndrome successfully treated with rituximabImmune-related adverse events of immune checkpoint inhibitors: a brief review
P2860
Q54215187-0345FFA7-7F2E-443C-93D7-B9F34889DF55Q54312209-7DBFD42F-1EA7-4C8F-88B8-CF43A51AA271Q55206910-57707835-B6C4-4ACA-8213-D69CA52D29A9Q55409972-28408CB2-A11E-4D37-95CA-4DC83B177F79Q55419474-EE507BF5-916E-436A-9F95-BDDF7F463A28Q55717841-D248695B-D373-4ADD-B61B-7011396F3F46Q56888756-288A67CE-26B4-47C6-9C06-F409ACB16679Q56892765-D0BD6CDF-9154-4B07-A14F-34803F6D766EQ57073426-7B0D5B23-A28A-4701-BC22-CCD4F3836A62Q57074555-7185DDF5-973C-4047-BA4F-9B5EFAF88E59Q57146198-82D69AB3-FDE7-43BB-B2D0-08C528E0B75BQ57280953-37EC77E5-572F-4FC8-A2F2-6106285B8917Q57803798-3C259C28-BAEB-41C4-A7A4-5F33B41FCDBDQ57810588-65E70084-F105-42C2-81A7-3DA323251B4FQ58698500-B01E455D-4D39-4B22-A040-5B74CADCAA70Q58760840-A7D96438-3119-4AC6-9621-D474F69A5650Q58779424-7B03BCCC-9AFF-4589-8913-311C019045DFQ58803053-FB19105B-B747-4A9C-B4CA-6A5D20FB3712Q59126189-4007E251-2B76-449F-9175-13C34B5A86CD
P2860
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Managing toxicities associated ...... city Management Working Group.
@en
Managing toxicities associated ...... ty for Immunotherapy of Cancer
@nl
type
label
Managing toxicities associated ...... city Management Working Group.
@en
Managing toxicities associated ...... ty for Immunotherapy of Cancer
@nl
prefLabel
Managing toxicities associated ...... city Management Working Group.
@en
Managing toxicities associated ...... ty for Immunotherapy of Cancer
@nl
P2093
P2860
P1476
Managing toxicities associated ...... city Management Working Group.
@en
P2093
C O Bingham
H L Kaufman
K Abdallah
P2860
P2888
P356
10.1186/S40425-017-0300-Z
P577
2017-11-21T00:00:00Z
P6179
1092818845